Skip to main content
    I

    InflaRx N.V. (IFRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.18
    +0.01 (+0.85%)

    Market Cap: $172.42M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    InflaRx N.V. (IFRX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in EUR.

    InflaRx reported revenue of EUR 29.33K for the fiscal year ended Dec 31, 2025, down 82.3% from the year before. That year, net income was EUR -45.63M with a net margin of -155582.1%, operating cash flow was EUR -33.92M and free cash flow was EUR -34.03M. The quarter ended Sep 30, 2026 had revenue of EUR 0 and net income of EUR -2.44M.

    Revenue and Margins

    Over the 8 years to Dec 2025, revenue fell from EUR 231.00K, a compound annual decline of 22.7%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 202529.33K-82.3%-24677.9%-164525.5%-155582.1%
    Dec 2024165.79K+162.8%-1900.8%-31911.4%-27785.0%
    Dec 202363.09KN/A-743.7%-70685.6%-67630.7%
    Dec 20220N/AN/AN/AN/A
    Dec 20210N/AN/AN/AN/A
    Dec 20200N/AN/AN/AN/A
    Dec 20190N/AN/AN/AN/A
    Dec 20180-100.0%N/AN/AN/A
    Dec 2017231.00KN/A-29.6%-8417.7%-10492.6%
    Dec 20160N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue29.33K165.79K63.09K00000231.00K0
    Cost of revenue7.27M3.32M532.26K627.01K791.26K812.47K742.25K179.57K66.69K35.66K
    Gross profit-7.24M-3.15M-469.17K-627.01K-791.26K-812.47K-742.25K-179.57K-68.42K-35.66K
    Research and development25.72M35.36M41.02M37.53M35.70M25.68M44.58M25.03M14.41M5.28M
    Operating income-48.26M-52.91M-44.59M-32.24M-47.63M-33.94M-56.77M-37.52M-19.45M-6.89M
    Net income-45.63M-46.06M-42.67M-29.48M-45.63M-33.98M-53.25M-29.82M-24.24M-8.94M
    EBITDA-45.16M-45.55M-42.06M-28.84M-44.94M-33.23M-56.11M-37.34MN/AN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue000-33.93K23.83K39.43K0-423123.82K6.36K36.04K2.29K
    Gross profit-85.14K0-88.61K-4.89M23.50K-2.36M-9.29K-2.82M196.37K-341.80K-184.48K-274.86K
    Operating income-5.54M-7.05M-7.21M-12.86M-9.48M-12.83M-13.01M-9.76M-15.36M-15.40M-12.49M-13.31M
    Net income-2.44M-10.65M-5.59M-10.64M-12.26M-14.42M-8.31M-5.11M-17.45M-13.85M-9.66M-15.93M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of EUR 256.83K by 15.76M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets55.19M76.02M120.21M102.40M125.14M88.22M121.58M159.21M124.21M29.52M
    Current assets53.61M71.66M109.47M97.41M95.68M86.28M118.99M158.16M123.98M29.38M
    Cash and equivalents16.02M18.38M12.77M16.27M26.25M25.97M33.13M55.39M123.28M29.12M
    Total liabilities13.65M14.60M17.63M14.05M19.86M10.35M14.43M7.82M4.78M55.21M
    Short-term debt256.83K406.02K374.33K369.38K366.17K338.52K515.20K0287.00K0
    Long-term debtN/AN/AN/AN/AN/AN/AN/A0053.44M
    Shareholder equity41.54M61.42M102.58M88.35M105.28M77.86M107.15M151.39M119.43M-25.69M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets161.32M166.84M48.94M55.19M65.16M73.44M87.00M76.02M79.69M93.04M107.10M120.21M
    Total liabilities17.22M20.72M12.01M13.65M19.79M16.40M16.53M14.60M14.41M10.88M12.34M17.63M
    Cash and equivalents81.34M146.51M15.01M16.02M6.45M13.00M47.29M18.38M26.21M19.15M25.10M12.77M
    Shareholder equity144.10M146.12M36.93M41.54M45.37M57.04M70.47M61.42M65.28M82.16M94.76M102.58M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-33.92M-48.56M-37.81M-33.74M-39.94M-36.53M-43.20M-23.71M-12.15M-4.99M
    Capital expenditures111.13K46.87K81.10K162.39K37.78K94.19K594.89K806.00K149.00K53.00K
    Free cash flow-34.03M-48.60M-37.89M-33.91M-39.97M-36.62M-43.80M-24.52M-12.30M-5.05M
    Investing cash flow3.11M52.36M-17.70M19.36M-25.95M21.36M20.34M-99.45M-167.00K-53.00K
    Financing cash flow32.00M386.45K52.99M1.94M61.58M9.17M-294.34K49.64M108.80M30.86M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-4.03M-2.57M-7.51M-4.71M-9.04M-7.55M-14.02M-11.89M-9.66M-12.13M-14.87M-10.88M
    Capital expenditures54.80K37.00K9.62K2.05K87.97K15.23K10.45K16.88K1.68K12.24K16.07K35.16K
    Free cash flow-4.09M-2.60M-7.52M-4.71M-9.13M-7.57M-14.03M-11.91M-9.66M-12.15M-14.88M-10.91M
    Last 12 quarters

    Frequently Asked Questions About IFRX

    What is InflaRx's annual revenue?

    InflaRx reported revenue of EUR 29.33K for the fiscal year ended Dec 31, 2025.

    How fast is InflaRx's revenue growing?

    Revenue was down 82.3% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is InflaRx profitable?

    No. InflaRx reported net income of EUR -45.63M for the fiscal year ended Dec 31, 2025, with a net margin of -155582.1%.

    How much free cash flow does IFRX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of EUR -33.92M minus capital expenditures of EUR 111.13K produced free cash flow of EUR -34.03M.

    How much debt does InflaRx have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of EUR 256.83K and cash and equivalents of EUR 16.02M.